Piper Sandler analyst Michael Lavery raised the firm’s price target on Hershey (HSY) to $180 from $167 and keeps a Neutral rating on the shares. The firm says it is updating its models and price targets for recently announced GLP-1 news, higher ABV headwinds, as well as tariff relief and other company specific updates. President Trump recently announced deals with Eli Lilly (LLY) and Novo Nordisk (NVO) to cut GLP-1 drug prices for Medicare and Medicaid beneficiaries in 2026 and offer the treatments directly to consumers at a discount on TrumpRX. Faster user uptake growth in the US appears directionally clear, and Piper now estimates about 20% of the U.S. population could be users by 2028.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSY:
- Video: Here’s who Wall Street calls the winners from food tariff relief
- Wall Street picks winners among food stocks benefiting from tariff relief
- Trump Trade: Trump ends reciprocal tariffs on food items including meat
- JPMorgan sees three major beneficiaries from reduced agricultural tariffs
- Piper sees three companies benefitting from updated Trump tariffs